Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Issued (2016 - 2025)

Syndax Pharmaceuticals has reported Shares Issued over the past 11 years, most recently at $11.2 million for Q4 2025.

  • Quarterly results put Shares Issued at $11.2 million for Q4 2025, up 456.17% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (up 607.76% YoY), and the annual figure for FY2025 was $12.1 million, up 607.76%.
  • Shares Issued for Q4 2025 was $11.2 million at Syndax Pharmaceuticals, up from -$80000.0 in the prior quarter.
  • Over the last five years, Shares Issued for SNDX hit a ceiling of $162.0 million in Q4 2022 and a floor of -$74.9 million in Q2 2021.
  • Median Shares Issued over the past 5 years was $506500.0 (2025), compared with a mean of $13.7 million.
  • Peak annual rise in Shares Issued hit 117087.5% in 2021, while the deepest fall reached 88167.06% in 2021.
  • Syndax Pharmaceuticals' Shares Issued stood at $81.2 million in 2021, then soared by 99.51% to $162.0 million in 2022, then plummeted by 99.83% to $277000.0 in 2023, then crashed by 1235.74% to -$3.1 million in 2024, then surged by 456.17% to $11.2 million in 2025.
  • The last three reported values for Shares Issued were $11.2 million (Q4 2025), -$80000.0 (Q3 2025), and $468000.0 (Q2 2025) per Business Quant data.